

ASX RELEASE

Business Update

Highlights:

- **After a third successive quarter of strong cash flows, Volpara has reduced its revolving credit facility from NZ\$10M to NZ\$2.5M**
- **Microsoft names Volpara global Healthcare & Life Sciences Partner of the Year**

Wellington, NZ, 4 July 2023: Volpara Health Technologies (ASX:VHT), a global leader in breast cancer detection software, today announced changes to its revolving credit facility and that it has won the global Microsoft Healthcare & Life Sciences Award for 2023.

Reducing revolving credit facility

In May of last year, Volpara obtained a [NZ\\$10M revolving credit facility](#) as part of its cash management planning. However, since the revised strategy's implementation in late [July 2022](#), with staffing changes complete in late August 2022, the business has operated on an approximately free cash flow break-even basis, with Q1FY24 delivering another strong quarter of cash inflows. With over NZ\$12M of cash on hand at the end of Q1FY24 and repeatable operating cash flow positivity in sight, the business has decided to reduce the revolving credit facility in place as it is no longer considered necessary. Management will evaluate the business's cash position over the next six months with a view to reducing the facility further. Volpara incurs a line fee of 1.5% p.a. of the available facility, with this change resulting in further cost savings of NZ\$112,500 per annum.

Volpara will report its full Q1FY24 results on Friday, 21 July 2023. A notification with a webinar link will be lodged with the ASX next week.

Microsoft global Healthcare & Life Sciences award

Volpara has won the global Healthcare & Life Sciences Partner of the Year Award, chosen from a set of more than 4,200 submitted nominations from more than 100 countries worldwide. This award recognises a partner organisation that excels at providing innovative healthcare and life sciences solutions based on Microsoft cloud technologies, driving customer growth, transformation, and enhanced patient care. Microsoft, a major investor in OpenAI, the maker of ChatGPT, supports Volpara in providing AI solutions to the breast cancer detection and prevention market.

In its mission to save families from cancer, Volpara hosts over 90 million mammograms on the Azure cloud, builds software on the Azure IoT platform, and protects sensitive information for more than 2,000 healthcare facilities with Microsoft Security.

Last year, a team of Microsoft experts arrived in Wellington to embark on a unique healthcare collaboration: the creation of a software product that detects and quantifies breast arterial calcifications (BAC), which can signal the presence of heart disease. Working alongside Volpara scientists and analysts, Microsoft provided guidance on using Microsoft's Azure Machine Learning platform to improve Volpara's BAC model and data processing. The project marked the beginnings

of a new application anticipated to enter Volpara into a new area of care and the US\$146.4B cardiovascular disease market.

Teri Thomas, Volpara CEO and Managing Director, said: “We are double delighted about this announcement. From a financial perspective, Volpara’s strategy continues to play out ahead of guidance, giving us the confidence to reduce reliance on banking facilities while simultaneously reducing costs. From a business perspective we are proud to be named Microsoft Partner of the Year in the global Healthcare & Life Sciences category. Microsoft is a great partner with an aligned philosophy that technology should be a force for global good, driving ongoing collaboration to develop new methods of disease detection, enhance our security stance, and reach new markets, which in the end are all meant to improve people’s lives.”

Authorisation & Additional Information

This announcement was authorised by the CEO & Managing Director of Volpara Health Technologies Limited.

ENDS

For further information, please contact:

Teri Thomas, CEO & MD
Volpara Health Technologies
teri.thomas@volparahealth.com
t: +64 4 499 6029

Hannah Howlett
WE Communications
WE-AUVolpara@we-worldwide.com
t: +61 407 933 437

About Volpara Health (ASX: VHT)

Volpara Health makes software to save families from cancer. We help leading healthcare providers have a positive impact on communities around the world. They use Volpara solutions to better understand cancer risk, empower patients in personal care decisions, and guide recommendations about additional imaging, genetic testing, and other interventions.

Our focus on customer value means that our AI-powered image analysis enables radiologists to quantify breast tissue with precision and helps technologists produce mammograms with optimal image quality. In an industry facing increasing staffing shortages, our software streamlines operations and provides key performance insights that support continuous quality improvement.

Volpara is a Certified B Corporation and holds the most rigorous security certifications and numerous patents and regulatory registrations, including FDA clearance and CE marking. Since listing on the ASX in April 2016, Volpara has raised A\$132 million. Volpara is based in Wellington, New Zealand, with an office in Seattle.

For more information, visit www.volparahealth.com.